SensOre

Share Purchase Plan Raises Additional $0.55 Million

SensOre (ASX: S3N or the Company) aims to become the top performing global minerals targeting company through deployment of big data, artificial intelligence/machine learning technologies and geoscience expertise.


SHARE PURCHASE PLAN

SensOre is pleased to announce that in addition to the $1m placement announced on 11 May 2023, the Company has raised a further $548,500 in the Share Purchase Plan (SPP). SensOre will issue 2,194,000 shares and 1,097,000 options to SPP participants today and will dispatch holding statements on Wednesday 14 June 2023, in accordance with the SPP timeline.

Under the terms of the SPP offer, eligible shareholders were entitled to purchase up to $30,000 worth of shares at a subscription price of $0.25 per share, being the same price as the share placement which was also announced on 11 May 2023. The SPP offer also included the issue of one option for every two shares at an exercise price of $0.375 and expiry of 3 years. The SPP offer closed on 7 June 2023.

The Company is in advanced negotiations with those who have expressed interest in taking a placement of the shortfall from the SPP.

This announcement was approved and authorised for release by the CEO.

Click here for the full ASX Release

This article includes content from SensOre, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

S3N:AU
The Conversation (0)
BlinkLab

Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism and other neurological conditions, is excited to announce results from the latest study in autism confirming high-accuracy in detecting autism in children ahead of upcoming FDA registrational study.

Keep reading...Show less
  Spectur Limited

Spectur Awarded Long Term Contract with Transport for NSW

Solar security, sensing and visual AI solutions and platforms company Spectur Limited (ASX: SP3) (Spectur or the Company) is pleased to announce the signing of a three-year contract for $787,428 with Transport for NSW (Contract No: CW2592803), with optional extensions to nine (9) years (Total price – nine year term - $2,632,284).

Keep reading...Show less
TSMC logo with chip.

Tech 5: TSMC Gets US$6.6 Billion Biden Admin Grant, Bitcoin Price Hits New All-time High

Bitcoin reached new levels this week, then paused amid speculation about how high it could go.

Meanwhile, the Biden administration finalized a multibillion-dollar arrangement to bring advanced semiconductor manufacturing back to the US, and a nuclear energy firm backed by Sam Altman announced data center supply deals.

Stay informed on the latest developments in the tech world with the Investing News Network's round-up below.

Keep reading...Show less
BlinkLab

BlinkLab Limited (ASX: BB1) – Trading Halt

Description

The securities of BlinkLab Limited (‘BB1’) will be placed in trading halt at the request of BB1, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 20 November 2024 or when the announcement is released to the market.

Keep reading...Show less
BlinkLab

BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for neurological conditions, is pleased to announce their participation in the landmark MAGNET (Monash Autism & ADHD Genetics and Neurodevelopment) study conducted by Monash University’s School of Psychological Sciences.

Link: https://molecularautism.biomedcentral.com/articles/10.1186/s13229-021-00457-3

Keep reading...Show less

Latest Press Releases

Related News

×